glp 1 drugs and birth control GLP-1 interactions: Here's what you need to know GLP-1 agonist tirzepatide and oral

DOI: 10.1016/j.drudis.2025.104333, Pratt, E., Ma, X., Liu, R., et al

[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity

Chen S, Yu SJ, Li Y, et al

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

There is no official link confirmed by regulatory bodies such as the MHRA or NICE stating that GLP-1 medications directly enhance fertility